Compounding is where the GLP-1 supply economy actually lives. The FDA's 2022–2024 shortage designations created a window for 503A patient-specific compounders and 503B outsourcing facilities to produce semaglutide and tirzepatide at a fraction of branded prices. Telehealth platforms — Hims & Hers, Ro, LifeMD, Eucalyptus — built distribution on top of that channel.
The window closed once the agency declared the shortages resolved. Since then, the rules have been rewritten in pieces: Category 2 placement for BPC-157 and other research peptides; the April 30, 2026 FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list; the Outsourcing Facilities Association lawsuit; and a University of Colorado secret-shopper study finding 65–69 of 74 medspas still sold compounded GLP-1s in April 2026. The Partnership for Safe Medicines applauded the 503B proposal and plans to file a Federal Register comment ahead of the June 29 deadline; Orrick's May client memo told outsourcing facilities, weight-loss clinics, and telehealth platforms still leaning on compounded supply to consult counsel.
Stories here cover both the legal and economic dimensions. See #503a, #503b, #category-2, and #fda for adjacent threads.
FormBlends, a telehealth platform focused on medically supervised GLP-1 and peptide therapy, released its 2026 State of Peptides and GLP-1 Regulation Report on April 28. The report maps how RFK Jr.'s HHS, the FDA Center for Drug Evaluation and Research, and the next-generation obesity pipeline from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping legal access for weight management, metabolic health, and peptide therapy through the end of the decade. The report follows the April 22 formal removal of 12 peptides from FDA Category 2 and previews the July 23-24 PCAC meeting.
Empower Pharmacy published a detailed industry analysis of the FDA's April 16 announcement removing 12 peptides from Category 2 and convening the July 23-24 PCAC meeting. The piece walks through the practical implications for compounding pharmacies, distinguishes Category 2 removal from Section 503A Bulk Drug Substances List inclusion, and emphasizes the gap between regulatory action and clinical access — physicians and patients are pressuring compounders to prepare peptides legally restricted only weeks ago.
Hyman, Phelps & McNamara's FDA Law Blog published a comprehensive two-part analysis April 22 walking compounders and peptide industry stakeholders through the Federal Register notice, the July 23-24 PCAC meeting structure, the distinction between Category 2 removal and Section 503A Bulk Drug Substances List inclusion, and the notice-and-comment rulemaking that must follow any PCAC recommendation. The analysis emphasizes that the July 9, 2026 written comment deadline and June 30 oral presentation notification are critical inflection points for industry engagement.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.
A University of Colorado Anschutz-led secret shopper study presented at Obesity Medicine Association 2026 surveyed 75 weight-loss clinics and medspas across two US states. 69 of 74 still offered compounded semaglutide and 65 of 74 offered compounded tirzepatide despite FDA resolving the name-brand shortages. Four source facilities had received FDA warnings or state licensing discipline since 2023 — three related to sterile compounding. Many clinics report using 'additive' formulations to skirt compounding restrictions.
CNBC analysis frames Hims & Hers Health as the biggest direct-to-consumer beneficiary of the FDA's July PCAC meeting. Hims acquired a California peptide manufacturing facility in 2025 and can convert its GLP-1 compounding infrastructure to peptide production. The stock closed up 11.07% on April 16 after the FDA announcement; Bank of America raised its price target from $21 to $25, citing the platform's conversion potential.
A BioCentury analysis argues the FDA's April 16 decision to convene a July Pharmacy Compounding Advisory Committee meeting on 12 previously restricted peptides reflects HHS Secretary RFK Jr.'s enthusiasm more than scientific evidence. The outlet warns that most of the peptides under review — for conditions spanning ulcerative colitis, wound healing, obesity, insomnia, and neurological disorders — lack robust clinical safety or efficacy data, and that ideology is increasingly shaping agency decisions.
Enhanced, an elite sports performance and direct-to-consumer peptide company, formally welcomed the FDA's Pharmacy Compounding Advisory Committee meeting schedule. CEO Maximilian Martin stated the reclassification will move peptides 'out of the grey market' and enable licensed compounding access. Enhanced plans to expand its Live Enhanced platform to offer additional peptides once they are formally moved to Category 1.
The Washington Post framed the FDA's upcoming July peptide panel through the lens of the exploding wellness craze, noting peptides are pitched as quick fixes for muscle building, injury healing, and anti-aging with minimal supporting research. When the FDA added 19 peptides to its restricted list in 2023, it cited safety risks including cancer and liver, kidney, and heart problems — concerns that have not been resolved.
The FDA announced it will convene the Pharmacy Compounding Advisory Committee on July 23-24 to evaluate whether seven or more peptides — including BPC-157, TB-500, and other popular wellness peptides — should be added to the list of substances eligible for pharmacy compounding. The announcement follows HHS Secretary RFK Jr.'s February pledge to reclassify 14 restricted peptides.
Hims & Hers Health Inc. jumped as much as 12% after the FDA's advisory panel announcement, with investors betting the telehealth company will benefit from expanded legal access to compounded peptide therapies. RFK Jr. stated on X that this action would 'immediately begin shifting demand away from the black market.'
The FDA published updated guidance clarifying compounding requirements now that semaglutide and tirzepatide shortages have been resolved. The statement reaffirmed enforcement deadlines for 503A and 503B pharmacies while acknowledging ongoing legal challenges from the Outsourcing Facilities Association.
ProPublica published a major investigation into the FDA's planned reversal on 19 restricted peptides, warning that reclassification under HHS Secretary RFK Jr. could expose consumers to inadequately tested drugs. The Alliance for Pharmacy Compounding acknowledged it knows little about the safety of individual peptides being sold to the public.
Wellness platform Noom acquired Tailor Made Compounding (TMC), a licensed 503A pharmacy operating in 46 states, marking its largest investment in healthy aging. Noom plans to expand its formulary to include peptide therapies like sermorelin and GHK-Cu alongside NAD+ and hormone treatments.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
The FDA is intensifying enforcement against compounding pharmacies selling unapproved GLP-1 products, threatening seizure and injunction. Hims & Hers was specifically named following the February 2026 TrumpRx launch.
Semaglutide injections officially removed from the FDA drug shortage list, though localized availability issues persist. Tirzepatide shortage status remains contested by the Outsourcing Facilities Association.
Noom acquired Tailor Made Compounding, a licensed 503A pharmacy in 46 states serving 400+ clinics, offering compounded peptides including sermorelin, GHK-Cu, and oxytocin.